Skye Bioscience Inc
NASDAQ:SKYE

Watchlist Manager
Skye Bioscience Inc Logo
Skye Bioscience Inc
NASDAQ:SKYE
Watchlist
Price: 5.39 USD -2% Market Closed
Market Cap: 163.5m USD
Have any thoughts about
Skye Bioscience Inc?
Write Note

Skye Bioscience Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Skye Bioscience Inc
Income from Continuing Operations Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Skye Bioscience Inc
NASDAQ:SKYE
Income from Continuing Operations
-$42.3m
CAGR 3-Years
-82%
CAGR 5-Years
-43%
CAGR 10-Years
-130%
Abbvie Inc
NYSE:ABBV
Income from Continuing Operations
$5.1B
CAGR 3-Years
-12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Income from Continuing Operations
$113m
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-36%
Amgen Inc
NASDAQ:AMGN
Income from Continuing Operations
$4.2B
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Income from Continuing Operations
-$479.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Income from Continuing Operations
$4.7B
CAGR 3-Years
-13%
CAGR 5-Years
17%
CAGR 10-Years
30%

See Also

What is Skye Bioscience Inc's Income from Continuing Operations?
Income from Continuing Operations
-42.3m USD

Based on the financial report for Jun 30, 2024, Skye Bioscience Inc's Income from Continuing Operations amounts to -42.3m USD.

What is Skye Bioscience Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-130%

Over the last year, the Income from Continuing Operations growth was -99%. The average annual Income from Continuing Operations growth rates for Skye Bioscience Inc have been -82% over the past three years , -43% over the past five years , and -130% over the past ten years .

Back to Top